Annual prescription costs for England reach £9.61 billion

10 June 2021

The cost of prescription items dispensed in England in 2020/21 was £9.61 billion ($13.6 billion). This was a 3.49% increase of £324 million from £9.28 billion in 2019/20 and a 7.41% increase of £663 million from £8.94 billion in 2014/15.

Published by NHS Business Services Authority, the annual Prescription Cost Analysis (PCA) includes information about the costs and volumes of prescriptions that have been dispensed in England. It is an Official National Statistics publication.

This is the second consecutive year that the cost of items dispensed in England has increased following three consecutive years of decreases between 2015/16 and 2018/19.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK